Clinical trials located in

Esplugues de Llobregat

Esplugues de Llobregat city is located in Spain. Currently, 18 clinical trials are being conducted in this city.

Esplugues de Llobregat, located in Catalonia, Spain, is known for its rich history and cultural heritage. This city, nestled near Barcelona, boasts a blend of modernity and tradition. It is renowned for its ceramics industry, which has been a significant part of its economy for centuries. Esplugues is also home to the Can Tinturé museum, displaying a unique collection of ceramic tiles, and the splendid Palau Reial de Pedralbes, reflecting its historical significance. The city’s landscape is marked by the Collserola mountain range, offering picturesque views and natural beauty.

  • CT-EU-00111794

    Exploring Delandistrogene Moxeparvovec for Duchenne Muscular Dystrophy

    The ENVISION trial is a research study focused on a new treatment for Duchenne Muscular Dystrophy (DMD), a condition that affects muscle strength. This trial is exploring a therapy called delandistrogene moxeparvovec, which is given through a vein. The purpose is to see if this treatment can improve muscle function by delivering a new gene to the body.

    This study is conducted on a large scale, involving many participants from different places, and is carefully controlled. Participants are randomly chosen to receive either the gene therapy or a placebo without knowing which one they are getting.

    The trial will go on for about 128 weeks (which is roughly 2 and a half years). An important part of the study is to see how the treatment might help with upper body movements, as these are essential for day-to-day tasks. Everyone in the study will eventually get a chance to receive the gene therapy, whether at the beginning or later on.

    ItalySpain
  • Testing a new drug (SAR442501) for safety and effectiveness in children with achondroplasia

    This is a Phase 2 clinical trial investigating the safety, tolerability, and efficacy of an investigational drug called SAR442501 in children from birth up to 12 years of age with Achondroplasia, a type of skeletal dysplasia. The study will involve administering SAR442501 as a subcutaneous injection (under the skin) to participants. The primary objective is to evaluate the number of participants who experience adverse events, serious adverse events, and adverse events of special interest during the first 52 weeks of treatment.

    The study will have a screening period of 3 weeks, followed by a 52-week primary treatment period, and then an extended treatment period of up to approximately 216 weeks (over 4 years). After completing the treatment periods, participants will undergo a 4-week follow-up period. The total duration of the study could be up to approximately 275 weeks (over 5 years).

    This clinical trial aims to gather important information about the safety profile, tolerability, and potential efficacy of SAR442501 in treating Achondroplasia, a rare skeletal disorder, in children. Participants will be closely monitored throughout the study to ensure their well-being and to collect valuable data that could contribute to the development of a potential new treatment option for this condition.

    ItalySpain
  • Research to enhance cancer treatments for kids and teens

    This clinical trial, known as CAMPFIRE, encompasses several studies testing new drugs for children and young adults with cancer. It includes various drug combinations such as Ramucirumab, Cyclophosphamide, Vinorelbine, Gemcitabine, Docetaxel, Abemaciclib, Irinotecan, and Temozolomide. These trials aim to evaluate the safety and effectiveness of these drugs in treating different cancer types. The study is interventional, with an estimated enrollment of 105 participants, randomized in parallel assignment. The primary purpose is treatment-focused.

    BelgiumFranceGermanyItalyNetherlandsSpainUnited Kingdom
  • Testing the effectiveness of a new drug compared with standard therapy in the treatment of asthma

    This medical research is a year-long study that tests a new asthma medication, called GSK3511294 (Depemokimab), against two other asthma medicines, Mepolizumab and Benralizumab. The trial is intended for teens and adults who have a severe form of asthma called ‘eosinophilic phenotype.’ The aim is to see if switching to GSK3511294 from Mepolizumab or Benralizumab keeps the severity and frequency of asthma attacks under control equally or better. Participants will keep taking their regular non-biological asthma medications throughout the trial. The study will look at the number of severe asthma attacks a patient experiences in a year, which is defined here as any worsening of asthma requiring steroids, a hospital visit, or an emergency room trip. They will also check for changes in their quality of life and their asthma control using questionnaires, and measure the capacity of their lungs with a breathing test.

    AustriaFinlandFranceGermanyItalyNetherlandsNorwayPolandPortugalSloveniaSpainSwedenUnited Kingdom
  • Study on the effectiveness of Ozanimod in treating Ulcerative Colitis

    This study is focused on evaluating the effectiveness and safety of ozanimod, a medication, in children with active ulcerative colitis, a challenging gastrointestinal condition associated with intense pain. The primary objective of the study is to investigate whether ozanimod, administered orally, can provide relief from the symptoms of active ulcerative colitis in children. Additionally, the study aims to assess the safety profile of ozanimod in this pediatric population.

    BelgiumFranceGermanyPolandSpainUnited Kingdom
  • Evaluating Delgocitinib’s effect on Chronic Hand Eczema

    This is a study designed for teenagers aged 12 to 17 who are experiencing long-term and severe cases of hand eczema. The research aims to investigate whether a cream containing delgocitinib can be effective in treating this condition and to assess any potential side effects. Delgocitinib works by reducing inflammation, a key aspect of the body’s response in diseases like eczema. The study duration is 22 weeks, during which each participant will use either the delgocitinib cream or a cream without the active ingredient twice daily. The study will closely monitor improvements in the participants’ eczema, the impact on their daily life, and any observed side effects.

    BelgiumFrancePolandSpainUnited Kingdom
  • Exploring the effectiveness and safety of Tisagenlecleucel in B-Cell Acute Lymphoblastic Leukemia treatment

    This study aims to investigate the efficacy of a new treatment called tisagenlecleucel in helping children and young adults combat B-cell Acute Lymphoblastic Leukemia (B-ALL), a high-risk form of blood cancer. The research is conducted across multiple hospitals and involves several stages, including eligibility assessments, treatment preparation, treatment administration, regular check-ups to monitor progress, and long-term follow-up. After receiving tisagenlecleucel, patients will have more frequent hospital visits in the initial month, followed by regular visits every few months for the first two years, and then annually until the study concludes, approximately eight years after the first patient undergoes treatment.

    BelgiumDenmarkFinlandGermanyItalyNetherlandsNorwaySpainSwedenUnited Kingdom
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    AustriaCzechiaFranceItalyRomaniaSpainUnited Kingdom
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    AustriaBelgiumFrancePolandUnited Kingdom
  • Study on carfilzomib effect on children’s leukemia

    This clinical trial focuses on children who face the difficult situation of acute lymphoblastic leukemia (ALL), a type of blood cancer. When cancer returns or does not respond to standard treatments, doctors call it relapsed or refractory, and it can be difficult to treat. The study is evaluating a drug called carfilzomib, which is being tested alongside common chemotherapy drugs. The drugs used in the clinical trial include carfilzomib, dexamethasone, mitoxantrone, PEG-asparaginase, vincristine, Intrathecal Methotrexate, Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate), 6-mercaptopurine, cyclophosphamide, cytarabine, and daunorubicin. The process has two main goals. First, he wants to find an appropriate dose of carfilzomib that is safe for children. This is significant because finding the right dose means balancing effectiveness with minimizing side effects. Once a safe dose is determined, the second part of the study begins. This part is about seeing how well carfilzomib works when it is part of a treatment regimen. Doctors and researchers will carefully monitor the children’s response to treatment. They will check whether the cancer responds to the new approach and how the children’s bodies cope with it. They will also track any side effects to ensure your treatment is safe.

    AustriaBulgariaCzechiaDenmarkFranceGreeceItalyNetherlandsNorwayPolandPortugalRomaniaSpainSweden
  • Examining apixaban treatment for venous thromboembolism

    This trial aims to evaluate the safety and efficacy of the medication Apixaban in the treatment of children with Venous Thromboembolism (VTE), a condition characterized by the formation of blood clots in the veins. Apixaban, functioning as a specialized agent, is intended to dissolve these clots. The primary objective of the trial is to assess the effectiveness of Apixaban in this regard. The evaluation will involve monitoring for any instances of major or minor bleeding events that may be attributed to the use of Apixaban, as well as investigating the recurrence of blood clots. Additionally, the concentration of Apixaban in the body and Anti-Xa Levels will be examined to further understand the pharmacokinetics of the medication.

    AustriaFranceGermanySpainUnited Kingdom
  • Comparison of the effectiveness of fingolimod and interferon in multiple sclerosis in children

    This study is about testing a medication called Fingolimod on young patients with Multiple Sclerosis (MS), a condition that affects the nervous system. The main purpose of this study is to check if this medication is safe and effective for these patients. The study will compare Fingolimod with another treatment, Interferon Beta-1a. The entire study will take about 7 years. In the first 2 years, patients will be randomly given either Fingolimod or Interferon Beta-1a without knowing which one they are receiving. In the next 5 years (Extension Phase), all the patients will take Fingolimod. The patients will include children and teenagers. There’s also a smaller group — the younger cohort — these are the kids who are 12 or younger, weigh less than 40 kg, or are not yet in puberty.

    FranceRomaniaSpainUnited Kingdom
  • Asthma treatment study for kids: comparing two medications

    This study is for children aged 6 to 11 with asthma. It compares the effectiveness and safety of two medications: QMF149 (a combination of indacaterol acetate and mometasone furoate) and budesonide. The study involves a cross-over design where children will receive both treatments for 12 weeks each, with a total duration of 37 weeks. It aims to find out which medication is better for controlling asthma symptoms in children. The study measures breathing function and asthma control. Safety and side effects are closely monitored. Participation could provide insights into better asthma management for kids.

    AustriaCzechiaGreeceHungaryItalyPortugalRomaniaSpain
  • Study of the safety and effectiveness of benralizumab in the treatment of asthma in children

    This study examines benralizumab, a potential asthma treatment for children aged 6-18 with severe eosinophilic asthma. Participants, receiving high-dose inhaled corticosteroids and additional medication, are randomly assigned to receive either benralizumab or a placebo without knowing which. The goal is to assess the drug’s effectiveness in reducing asthma exacerbations and improving overall asthma control. Following the initial phase, all participants will receive benralizumab in an open-label extension, monitoring safety and response.

    FranceGermanyItalyPolandSpainUnited Kingdom
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    BelgiumDenmarkFinlandFranceGermanyNetherlandsNorwayPortugalSwedenUnited Kingdom
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    AustriaBelgiumFranceGermanyItalySpain
  • Pediatric trial assessing apixaban for venous thromboembolism

    This is a trial to evaluate the effectiveness and safety of a medicine called apixaban in children who need anticoagulation treatment due to venous thromboembolism (VTE), a condition where blood clots form in the vein. The study aims to describe how well apixaban works in treating VTE in children compared to the standard treatments. The standard treatments may include other anti-coagulants such as unfractionated heparin, low molecular weight heparin, or a vitamin K antagonist. Apixaban will be given to children from birth to less than 18 years old, based on a weight-tiered regimen. This research is key to understanding the best possible treatment for children dealing with VTE, and participants’ safety will be closely monitored throughout the study.

    AustriaFranceGermanySpainUnited Kingdom
  • Safety and efficacy study of lebrikizumab for atopic dermatitis in children and adolescents

    A clinical trial to test the safety and efficacy of a drug called lebrikizumab in children and adolescents suffering from moderate to severe atopic dermatitis, commonly known as eczema. The study involves participants between the ages of 6 months and 18 years to monitor how well their bodies absorb the drug. Participants receive a saturating dose of the drug, followed by subsequent doses. The number of doses depends on the participant’s weight. The study also includes a control group that will receive a placebo. The effect of the treatment will be measured by various tests, such as the severity index, itch score and quality of life index.

    CzechiaFranceGermanyPolandSpain

See more clinical trials in other cities in Spain:

.